A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10).
Cancer Res Treat. 2023 May 25. Online ahead of print.
Imatinib in c‑KIT‑mutated metastatic solid tumors: A multicenter trial of Korean Cancer Study Group (UN18‑05 Trial)
Journal of Cancer Research and Therapeutics. April 04, 2023.
A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21)
J Thorac Oncol. 2023 Feb;18(2):223-231.
Status of Using Complementary and Alternative Medicine among Patients with Cancer in Korea: an Online Survey of Online Cancer Support Groups (KCSG PC21-20)
Cancer Res Treat. 2023 Apr;55(2):442-451.
A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
Cancer Res Treat. 2023 Apr;55(2):523-530.
Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O6-Methylguanine DNA Methyltransferase Status: KCSG-CO17-02
Clin Oncol (R Coll Radiol). 2023 Feb;35(2):e143-e152
Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01)
Cancers(Basel). 2023 Jan 12;15(2):471.
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)
Lancet Gastroenterol Hepatol. 2023 Jan;8(1):56-65.
A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11)
Clin Lung Cancer. 2022 Dec;23(8):e536-e539.
Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study Group
Ther Adv Med Oncol. 2022 Nov 2;14:17588359221132628.
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)
